Metabolic Genetics PhD: Investigating Fat Distribution with Population Data and Gene Editing

Metabolic Genetics PhD: Investigating Fat Distribution with Population Data and Gene Editing

Quick Decision

This four-year MRC FGx-DLA project links multi-ancestry genetic discovery to functional tests of human fat cells. The Exeter work would prioritize coding and non-coding variants associated with fat distribution; the Cambridge work would build iPSC-derived visceral and subcutaneous adipocyte models and test selected candidates with CRISPR, imaging and biochemical assays. This combination suits applicants who want both population genetics and laboratory validation.

One term in the project PDF needs clarification: it places visceral fat beside “lipodystrophy,” although the latter usually refers to deficient or dysfunctional adipose tissue, not ordinary visceral-fat accumulation. Ask which phenotype the project will study. Exeter lists 5 January 2027; an earlier vacancy record gives 8 December 2026 and mislabels the funder. Confirm the deadline, international-fee terms, Cambridge supervision and cross-site registration plan before committing.

Research Problem and Doctoral Work

What is unresolved and why it matters

Body-fat distribution can shape cardiometabolic risk independently of total body mass. Common GWAS have identified many associated loci, but the causal non-coding variants, target genes and tissue-specific regulatory mechanisms remain difficult to assign. A 2022 multi-ancestry exome study of 618,375 people found rare coding variants associated with BMI-adjusted waist–hip ratio and showed that fat-distribution associations can differ from overall adiposity; a 2025 analysis likewise modelled fat distribution as a distinct genetic factor. These findings support the project's focus on depot-specific biology rather than BMI alone.

The project asks which regulatory elements and genes drive differences between human visceral and subcutaneous adipocytes. Its advertised sequence is: (1) use multi-ancestry WGS and fat measurements to discover coding and non-coding associations; (2) integrate expression, chromatin accessibility and enhancer–gene maps with AlphaGenome predictions to prioritize candidate variants, regulatory elements and genes; (3) derive iPSC adipocytes patterned toward visceral or subcutaneous identity; and (4) measure effects of prioritized genes or variants after CRISPR perturbation. The project names DNANexus Cloud Trusted Research Environments for analysis of more than one million genomes, but cohort-specific sample sizes, data approvals and compute allocations are not stated.

Methods, validation and potential outputs

At Exeter, existing population-genetic association pipelines will connect WGS variants to fat-distribution measurements. Multi-ancestry analysis can improve discovery and portability, but its value depends on cohort composition, phenotype quality, ancestry-specific sample sizes and handling of population structure. The project should report those features rather than equating “multi-ancestry” with equal power across populations.

Regulatory maps and AlphaGenome can help rank non-coding candidates by predicted molecular effects. AlphaGenome accepts up to 1 Mb of DNA sequence and predicts multiple regulatory modalities; its benchmark results are promising, but its scores are hypotheses for follow-up, not proof that a variant acts in a human adipocyte or causes a clinical outcome. Ask which adipose depots/cell states the available maps represent, how enhancer–gene links will be assigned, and how prediction calibration and ancestry transfer will be tested.

At Cambridge, the PDF describes developmental-cue-guided differentiation of iPSCs toward visceral and subcutaneous adipocyte identities, a stable Cas9-expressing iPSC line, benchmark perturbations of ALK7/ACVR1C and PLIN1, high-content imaging and biochemical assays for adipogenesis, lipid storage and lipolysis, followed by a primary CRISPR knockout screen of genetically prioritized candidates. A 2024 human-adipocyte study combining population genetics and CRISPR knockout work demonstrates why this genetics-to-function progression is plausible. However, the project PDF does not specify the editing strategy for individual non-coding regulatory variants; a gene knockout screen and precise non-coding-variant tests answer different questions. Ask whether the plan includes base/prime editing, enhancer perturbation or another variant-level assay, and how depot identity and iPSC differentiation maturity will be benchmarked.

The advertised outcome is a validated human iPSC-adipocyte platform, mechanistic evidence for non-coding variants affecting fat distribution and candidate cardiometabolic targets related to safer fat storage. The scope is ambitious: population-genetic discovery, regulatory interpretation, two depot-like cell states, assay optimization and a primary screen must fit a four-year studentship. The exact candidate count and staged milestones remain unspecified.

Scientific terminology that needs clarification

The PDF calls visceral fat “lipodystrophy” in a parenthetical. Endotext and clinical guidance describe lipodystrophy syndromes as rare conditions involving partial or generalized absence of adipose tissue and impaired storage; partial forms can include relative accumulation in preserved depots. This is related to fat partitioning but is not synonymous with ordinary visceral adiposity. Ask the team whether the intended phenotype is general visceral-versus-subcutaneous distribution, monogenic/clinical lipodystrophy, or both, and how each will be operationalized in cohort phenotypes and cell models. This matters for interpreting inclusion criteria, endpoints and the clinical collaborators’ role.

School, Programme and Field Context

The official project PDF names the University of Exeter as primary institution and the Department of Clinical and Biomedical Sciences. Exeter’s research-degree page lists an MPhil/PhD in Clinical and Biomedical Sciences, and describes relevant activity in molecular genetics, diabetes, complex-disease epigenetics, data science and AI. It reports Exeter in the top 10 in the UK for world-leading and internationally excellent Clinical Medicine research based on REF 2021, while separately citing THE World University Rankings 2026 subject positions of top 125 for Life Sciences and top 175 for Medical and Health. These signals describe the department/university, not this particular project. The project’s precise registration route, campus and formal degree-awarding arrangements have not been stated in its PDF; confirm that Exeter will award the degree and clarify any Cambridge registration or site requirements rather than assuming a joint degree.

The MRC FGx-DLA provides a four-year award with part-time study available, and the national programme describes shared cohort activities, scientific meetings, cross-institution training and interdisciplinary supervision. The official project divides work between Exeter and Cambridge. Cambridge’s Institute of Metabolic Science has broad obesity/diabetes, genetics and cell-biology expertise, but the project PDF does not name the Cambridge supervisor or specific lab; confirm the host group, day-to-day supervisor and expected time at each site. The award does not spell out a project-specific curriculum or compulsory training modules.

Supervisor and Lab Assessment

Lead supervisor and research direction

The official project PDF names Michael Weedon as lead supervisor and provides his Exeter email. The Exeter staff directory lists him as a professor; a current UK Biobank project listing also identifies him as PI for research using population genetics to understand human traits and disease. The project is consistent with an Exeter strength in population genetics and large-cohort analysis. The Cambridge experimental side and the senior clinical academics mentioned in the project PDF are not named, so their specific roles, availability and supervisory frequency remain open questions.

Recent publications and relevance

• Hawkes et al. (2026), “Whole-genome sequencing analysis of anthropometric traits in 672,976 individuals…” includes Weedon and Exeter colleagues. It combines UK Biobank discovery (447,461) with All of Us replication (225,515), reporting rare and low-frequency associations for anthropometric phenotypes. This supports the team’s capacity for WGS-scale statistical genetics; its headline traits are anthropometric, not direct experimental comparisons of depot-specific adipocytes.
• Sharp et al. (2026), “Genotype-first approach reveals monogenic lipodystrophy is underdiagnosed…” includes Weedon and uses UK Biobank WGS to identify 31 pathogenic-genotype carriers among 490,414 participants. This shows relevant clinical-genetic expertise, while also reinforcing that monogenic lipodystrophy is a distinct and rare phenotype. Small carrier counts and volunteer-cohort selection limit generalization.
• Laver et al. (2022), “PLIN1 Haploinsufficiency Causes a Favorable Metabolic Profile,” reports population associations between PLIN1 protein-truncating variants and favorable waist–hip ratio/metabolic traits. Its relevance is direct because the project proposes PLIN1 as an assay benchmark; an association does not by itself prove a specific iPSC perturbation result.

The project PDF also cites a 2025 SREK1 study linking rare variants to a Prader-Willi-like syndrome. This provides adjacent variant-to-mechanism context, but it is not a fat-depot study and should not be taken as evidence that the same pathway is a project target.

Facilities and collaboration

The project specifies Exeter large-scale computational resources and DNANexus TRE access for more than one million genomes, plus Cambridge iPSC, high-content imaging and flow cytometry facilities. The initiative’s national cohort may offer additional cross-institutional training. Public evidence does not establish the precise cohort-access approvals, exact Cambridge group, microscope/flow availability, training calendar, travel budget or the percentage of the PhD spent at each site. These are operational facts to confirm with the named lead and admissions team.

Funding, Application, and Living Cost

The Exeter MRC FGx-DLA page and Award Ref. 6025 list a four-year studentship, available part-time, with UK tuition fees, the UKRI minimum stipend of £21,805 per year for 2026/27 (updated annually) and up to £5,000 per year for research training and support. The captured job notice falsely labels the award as EPSRC; the official project PDF and Exeter pages confirm MRC FGx-DLA.

For international applicants, distinguish the award page’s narrower wording from the current national initiative guidance: the award says “UK tuition fees,” while the national FGx-DLA postgraduate page explicitly says Exeter students do not need to supplement UKRI funding with an international fee difference. UKRI general guidance says its grant only contributes up to the home-fee rate, so the programme-specific Exeter statement is the relevant exception. Ask admissions to confirm this rule applies to this award and appears in the written offer. UKRI does not pay visa fees or the Immigration Health Surcharge (IHS).

Exeter estimates basic living costs at £1,300–£2,000 per month, based on local spending in April 2026. Dividing the current full-time stipend by 12 gives about £1,817 per month. This is only a rough comparison: the stipend falls within the university’s broad budget range, so housing choice and lifestyle will matter; deposits, visa/IHS and travel can add upfront costs. The separate £5,000 research-support budget is not living money and its use is subject to the project’s arrangements.

The official programme and award pages list 5 January 2027 as the deadline for September 2027 entry. A captured notice lists 8 December 2026, alongside the incorrect EPSRC label. It may be an old or erroneous date; prepare to the earlier date while asking Exeter PGR admissions to confirm the final cut-off time and time zone.

Eligibility requires at least a 2:1 honours degree (or international equivalent) in a relevant discipline. Listed subjects include genetics, molecular biology, biomedical science, human biology, biochemistry, medicine, healthcare professions, bioinformatics, computer science and statistics. The typical language requirement is IELTS 7.0 overall, with no component below 6.5, or equivalent. Apply through Exeter’s online form and complete the FGx-DLA questionnaire; supply transcripts, a CV no longer than two pages, two references and English-language evidence where required. One application per person is accepted, with up to three project preferences in the questionnaire. Referees must be outside the prospective supervisory team; if shortlisted, the applicant must arrange for academic references to arrive seven days before interview. Application materials must be in English, with certified translations of academic documents where required.

Applicant Fit and Preparation

The advertised eligibility spans both biological and quantitative backgrounds. Applicants with genetics, bioinformatics, statistics or computational genomics experience may be well positioned for the cohort-analysis and regulatory-prioritization stages; those from molecular biology, biomedical science or related fields may be able to contribute strongly to iPSC, assay and CRISPR work. The central challenge is crossing the computational-to-experimental boundary, not arriving as an expert in every method.

The official listing does not make a specific programming language, stem-cell credential or CRISPR track record a separate eligibility condition. Useful preparation—not a formal prerequisite—would include reproducible R/Python analysis, population-structure and association methods, familiarity with adipose phenotypes and regulatory genomics, and evidence of careful wet-lab or cell-model work. Applicants should be ready to explain how they learn unfamiliar methods and validate computational predictions experimentally.

Career routes could include academic statistical/functional genomics, biotech or pharmaceutical discovery, research bioinformatics, translational metabolism and related data-science roles. Skills England projects roughly 66,000 additional jobs in selected life-sciences priority occupations between 2025 and 2035, plus around 52,000 replacement demand, while warning that projections are uncertain and many occupations compete with digital/technology sectors. This broad sector evidence does not predict employment for one PhD graduate; the project’s mixed human-genetics, machine-learning and cell-assay training may create options, but direct industry placement or career guarantees are not stated.

Next Actions and Questions to Verify

Before applying

1. Ask Exeter PGR admissions to confirm whether 5 January 2027 is the operative deadline, the exact time/time zone, and whether the conflicting 8 December 2026 date has any effect on this specific project.
2. Confirm that this is MRC FGx-DLA Ref. 6025 and request written confirmation that Exeter’s no-international-fee-top-up policy applies to the award. Ask how the offer will specify tuition, the 2027/28 stipend, annual £5,000 support terms, visa/IHS exclusions and the international-student cap.
3. Confirm the registered degree, degree-awarding institution, campus/base location, Cambridge host group and any cross-site attendance or registration requirements.
4. Prepare the single online application, questionnaire, transcripts, two-page CV, two external references and English evidence where applicable. Do not submit duplicate applications; use the questionnaire for up to three preferences.

At interview

• Does the project focus on visceral-versus-subcutaneous adiposity, clinical/monogenic lipodystrophy, or both? How will each phenotype be defined in data and cell models?
• Which WGS cohorts and adipose regulatory maps are already approved, what are their ancestry composition and usable sample sizes, and what is the DNANexus access/compute plan?
• What methods will perturb non-coding elements or individual variants, beyond the primary CRISPR knockout screen of prioritized genes?
• How will iPSC-derived cells be assessed for depot identity, differentiation maturity, batch variation and reproducibility? What are the planned assay controls for ALK7/ACVR1C and PLIN1?
• Which Cambridge supervisor/lab will host the experimental work, who leads day-to-day supervision at both sites, and how is time divided across Exeter and Cambridge?
• What are the staged milestones and fallback plan if cohort approvals, cell differentiation or the first screen are delayed?

Before accepting an offer

Obtain written confirmation of the tuition arrangement, stipend and duration, start date, degree registration, site split, named supervisory team, confirmed data permissions and the deliverables expected within four years. Clarify whether any research or travel costs could exceed the annual support allocation.

Evidence and Sources

Core project, programme and school

• Official MRC FGx-DLA project PDF
• Exeter MRC FGx-DLA programme and 2027 project directory
• Exeter award record Ref. 6025
• National FGx-DLA postgraduate and international fee guidance
• UKRI support, stipend, tuition and visa/IHS guidance
• Exeter Clinical and Biomedical Sciences research degrees
• Exeter Clinical and Biomedical Sciences research themes
• University of Exeter REF 2021 results

Supervisor, institution and recent research

• Exeter Clinical and Biomedical Sciences staff directory
• Michael Weedon’s current UK Biobank project record
• Michael Weedon’s ORCID record
• Hawkes et al. (2026), WGS analysis of 672,976 people
• Sharp et al. (2026), genotype-first lipodystrophy study
• Laver et al. (2022), PLIN1 haploinsufficiency and metabolic profile
• Saeed et al. (2025), SREK1 and a Prader-Willi-like syndrome
• Cambridge Institute of Metabolic Science — Metabolic Research Laboratories
• Toni Vidal-Puig Laboratory, Cambridge metabolic research

Field methods and interpretation

• Avsec et al. (2026), AlphaGenome regulatory variant prediction
• Genomic architecture of adiposity and fat distribution (2025)
• Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots
• Multi-ancestry INHBE study of fat distribution and diabetes
• Human genetics and functional screens in obesity and fat distribution (2024)
• Endotext clinical definition of lipodystrophy syndromes

Funding, cost and careers

• Exeter living-cost estimate
• Skills England 2026 Life Sciences skills assessment
• UK Life Sciences Jobs Plan (2026)